Progress and new directions in genetics of tuberculosis: An NHLBI Working Group report

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 12, 2005, Pages 1491-1496

  Smith, Issar ^a   Nathan, Carl ^a   Peavy, Hannah H ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Bacterial virulence factors; Genetics; Host immunologic response; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

ISONIAZID;

BACTERIAL GENETICS; BACTERIAL GENOME; BACTERIAL VIRULENCE; BIOINFORMATICS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; GENE EXPRESSION; GENE LOCUS; HUMAN; IMMUNE RESPONSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 30444431938     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200506-997WS     Document Type: Conference Paper

References (65)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-686.
2. Tobin MJ. Tuberculosis, lung infections, interstitial lung disease, and journalology in AJRCCM 2002. Am J Respir Crit Care Med 2003;167:345-355.
3. Tobin MJ. Tuberculosis, lung infections, interstitial lung disease, social issues and journalology in AJRCCM 2003. Am J Respir Crit Care Med 2004;169:288-300.
4. Nemery B, Yew WW, Albert R, Brun-Buisson C, Macnee WF, Martinez JD, Angus C, Abraham E. Tuberculosis, nontuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004. Am J Respir Crit Care Med 2005;171:554-562.
5. Colditz, GA, Brewer,TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702.
6. Smith CV, Sharma V, Sacchettini JC. TB drug discovery: addressing issues of persistence and resistance. Tuberculosis 2004;84:45-55.
7. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001;163:1055-1058.
8. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE, Freedman VH, Kaplan G. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci USA 2001;98:5752-5757.
9. Hopewell PC. Overview of clinical tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington, DC: American Society for Microbiology; 2000. pp. 25-46.
10. Wallgren A. The time table of tuberculosis. Tubercle 1948;29:245-251.
11. Kamholz SL. Pleural tuberculosis. In: Rom WN, Garay S, editors. Tuberculosis. Boston: Little, Brown and Co; 1996. pp 483-491.
12. Paolo WF, Nosanchuk JD. Tuberculosis in New York City: recent lessons and a look ahead. Lancet Infect Dis 2004;4:287-293.
13. Garay S. Tuberculosis and the human immunodeficiency virus infection. In: Rom WN, Garay S, editors. Tuberculosis. Boston: Little, Brown and Co; 1996. pp. 443-465.
14. Kaye K, Frieden T. Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Epidemiol Rev 1996;18:52-63.
15. Bekker LG, Moreira AL, Bergtold A, Freeman S, Ryffel B, Kaplan G. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun 2000;68:6954-6961.
16. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun 1998;66:1277-1281.
17. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995;63:736-740.
18. Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages in patients with active pulmonary tuberculosis. J Exp Med 1996;183:2293-2302.
19. Choi HS, Rai PR, Chu HW, Cool C, Chan ED. Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med 2002;166:178-186.
20. Wieland CW, Knapp S, Florquin S, de Vos AF, Takeda K, Akira S, Golenbock DT, Verbon A, van der Poll T. Non-mannose-capped lipoarabinomannan induces lung inflammation via toll-like receptor 2. Am J Respir Crit Care Med 2004;170:1367-1374.
21. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT, Boom WH, Harding CV. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol 2001;167:910-918.
22. Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect Immun 1996;64:683-690.
23. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003;302:654-659.
24. van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 2002;15:294-309.
25. Algood HM, Lin PL, Yankura D, Jones A, Chan J, Flynn JL. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 2004;172:6846-6857.
26. Dannenberg AM, Rook JA. 1994. Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses. Dual mechanisms that control bacillary multiplication. In: Bloom BR, editor. Tuberculosis. Pathogenesis, protection and control. Washington, DC: ASM Press; 2004. 459-483.
27. MacMicking JD. North R, LaCourse R, Mudgett, J, Shah S, Nathan C. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997;94:5243-5248.
28. Flynn JL, Scanga CA, Tanaka KE, Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 1998;160:1796-1803.
29. Rees JRW, Hart PDA. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacilary counts. Br J Exp Pathol 1961;42:83-88.
30. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054-2058.
31. Munoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 2005;73:546-551.
32. Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S, Fuhrman C, Klein E, Flynn JL. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003;71:5831-5844.
33. Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L, Kou Z, Wang Q, Jiang L, Estep J, et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 2002;295:2255-2258.
34. Converse PJ, Dannenberg AM, Estep JE, Sugisaki K, Abe Y, Schofield BH, Pitt ML. Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun 1996;64:4776-4787.
35. Pathan AA, Wilkinson KA, Wilkinson RJ, Latif M, McShane H, Pasvol G, Hill AV, Lalvani A. High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. Eur J Immunol 2000;30:2713-2721.
36. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu, L, Alderson MR, Lewinsohn DM. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 2003;168:1346-1352.
37. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000;30:3689-3698.
38. Teitelbaum R, Cammer M, Maitland ML, Freitag NE, Condeelis J, Bloom BR. Mycobacterial infection of macrophages results in membrane-permeable phagosomes. Proc Natl Acad Sci USA 1999;96:15190-15195.
39. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
40. Schaible UE, Winau F, Sieling PA, Fischer K. K, Collins HL, Hagens K, Modlin RL, Brinkmann, V, Kaufmann SH. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003;9:1039-1046.
41. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
42. Segal W, Bloch H. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bacteriol 1956;72:132-141.
43. Segal W, Bloch H. Pathogenic and immunogenic differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. Am Rev Tubercl Pulm Dis 1957;75:495-500.
44. McKinney JD, Bentrup KHZ, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR, Russell DG. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxalate shunt enzyme isocitrate lyase. Science 2000;406:735-738.
45. Ohno H, Zhu G, Mohan VP, Chu D, Kohno S, Jacobs WR, Chan J. The effects of reactive nitrogen intermediates on gene expression in Mycobacterium tuberculosis. Cell Microbiol 2003;5:637-648.
46. Shi L, Jung YJ, Tyagi S, Gennaro ML, North RJ. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci USA 2003;100:241-246.
47. Pelicic V, Reyrat JM, Gicquel B. Genetic advances for studying Mycobacterium tuberculosis pathogenicity. Mol Microbiol 1998;28:413-420.
48. Glickman MS, Jacobs WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 2001;104:477-485.
49. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eigenmeir K, Gas S, Barry C III. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-544.
50. Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002;184:5479-5490.
51. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci USA 2004;101:4871-4876.
52. Sassetti C, Rubin EJ. Genomic analyses of microbial virulence. Curr Opin Microbiol 2002;5:27-32.
53. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003;16:463-496.
54. Domenech P, Reed MB, Dowd CS, Manca C, Kaplan G, Barry CE. The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem 2004;279:21257-21265.
55. Kramnik I, Dietrich WF, Demant P, Bloom BR. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000;97:8560-8565.
56. Sanchez F, Radaeva TV, Nikonenko BV, Persson AS, Sengul S. Schalling, Schurr ME, Apt AS, Lavebratt C. 2003. Multigenic control of disease severity after virulent Mycobacterium tuberculosis infection in mice. Infect Immun 2003;71:126-131.
57. Kamath AB, Alt J, Debbabi H, Taylor C, Behar SM. The major histocompatibility complex haplotype affects T-cell recognition of mycobacterial antigens but not resistance to Mycobacterium tuberculosis in C3H mice. Infect Immun 2004;72:6790-6798.
58. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005;434:767-772.
59. Sousa AO, Salem JI, Lee FK, Vercosa MC, Cruaud P, Bloom BR, Lagrange PH, David HL. An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Proc Natl Acad Sci USA 1997;94:13227-13232.
60. Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P, Bester D, Meyer M, Corrah T, Collin M, et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci USA 2000;97:8005-8009.
61. Segal S, Hill AV. Genetic susceptibility to infectious disease. Trends Microbiol 2003;11:445-448.
62. Zhang W, Shao L, Weng X, Hu Z, Jin A, Chen S, Pang M, Chen ZW. Variants of the natural resistance-associated macrophage protein 1 gene (NRAMP1) are associated with severe forms of pulmonary tuberculosis. Clin Infect Dis 2005;40:1232-1236.
63. Cervino A. C, Lakiss S, Sow O, Bellamy R, Beyers N, Hoal-van Helden E, van Helden P, McAdam KP, Hill AV. Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families. Hum Mol Genet 2002;11:1599-1603.
64. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998;338:640-644.
65. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther 2005;12:634-638.